Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity

Exclusion Criteria

• •Any current prescribed anti-obesity medications (AOM) such as Orlistat, Phentermine, Qsymia (Phentermine/Topiramate), Liraglutide, Semaglutide, and Setmelanotide
• •Any current prescribed anti-hypertensive medications
• •Any specific end-organ acute concerns (kidney disease, liver disease, congenital disease).
• •Any active infections at enrollment.
• •Any systemic steroid use longer than 3 month use or within the last month before enrollment (not including inhaled, ophthalmic, intranasal, and topical).
• •Any limitations that would make exercise testing not possible.
• •Any congenital abnormality or genetic syndrome known to be associated with obesity
• •Pregnancy
• •Inability to receive an MRI
• •Personal or family history of medullary thyroid carcinoma (per product insert)
• •Patients with Multiple Endocrine Neoplasia syndrome type 2 (per product insert)